LATEST NEWS
December 31, 2019 | Company Announcements
Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash PreparednessDecember 17, 2019 | Company Announcements
Bavarian Nordic Announces the Sale of Priority Review VoucherDecember 13, 2019 | Company Announcements
Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKlineNovember 27, 2019 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held November 27, 2019November 13, 2019 | Company Announcements
Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial OfficerNovember 07, 2019 | Company Announcements
Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine RegimenNovember 07, 2019 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 07, 2019 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2019October 25, 2019 | Company Announcements
Bavarian Nordic A/S – Notice Convening Extraordinary General Meeting October 21, 2019 | Company Announcements
Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline